Trial Profile
A Phase 1, Multicenter, Open-Label, Dose-Escalation, Safety, Pharmacokinetic, and Pharmacodynamic Study of E6201 in Subjects With Advanced Solid Tumors.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 17 Oct 2022
Price :
$35
*
At a glance
- Drugs E 6201 (Primary)
- Indications Malignant melanoma; Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Eisai Inc
- 12 Oct 2022 Status changed from active, no longer recruiting to completed.
- 05 Jun 2018 Results published in the British Journal of Cancer
- 22 Jul 2014 Planned End Date changed from 1 Jan 2014 to 1 Feb 2015 as reported by ClinicalTrials.gov.